{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:26:20Z","timestamp":1792589180738,"version":"4.5.0"},"reference-count":336,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.metabol.2026.156494","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:51:55Z","timestamp":1768920715000},"page":"156494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Emerging incretin- and multi-agonist-based treatments \u2013 the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond"],"prefix":"10.1016","volume":"177","author":[{"given":"Emir","family":"Muzurovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160pela","family":"Vol\u010dan\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Plescia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2026.156494_bb0005","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.metabol.2026.156494_bb0010","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: pathophysiology and emerging pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2026.156494_bb0015","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(18)30288-2","article-title":"Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3\u00b76 million adults in the UK","volume":"6","author":"Bhaskaran","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156494_bb0020","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2026.156494_bb0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1570161115666170621075619","article-title":"Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?","volume":"16","author":"Katsiki","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.metabol.2026.156494_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155664","article-title":"From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","volume":"147","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154333","article-title":"Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)\/DASH (dysmetabolism associated steatohepatitis)","volume":"114","author":"Katsiki","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","article-title":"New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics","volume":"74","author":"Jastreboff","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154305","article-title":"Commentary: from mice to men: in search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based","volume":"109","author":"Muzurovi\u0107","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108359","article-title":"Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients","volume":"36","author":"Muzurovi\u0107","year":"2022","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.metabol.2026.156494_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155689","article-title":"Milestones in the journey towards addressing obesity; past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery","volume":"148","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.21037\/atm.2017.03.107","article-title":"Morbidity and mortality associated with obesity","volume":"5","author":"Abdelaal","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0070","first-page":"S24","article-title":"Dietary patterns in non-alcoholic fatty liver disease (NAFLD): stay on the straight and narrow path!","volume":"34","author":"Katsiki","year":"2022","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.metabol.2026.156494_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/nutrit\/nux014","article-title":"Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation","volume":"75","author":"P\u00e9rez-Mart\u00ednez","year":"2017","journal-title":"Nutr Rev"},{"key":"10.1016\/j.metabol.2026.156494_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106679","article-title":"Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): a position paper from the International Lipid Expert Panel (ILEP)","volume":"189","author":"Rizzo","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2026.156494_bb0085","doi-asserted-by":"crossref","first-page":"9760","DOI":"10.3390\/ijms24119760","article-title":"A critical view over the newest antidiabetic molecules in light of efficacy\u2014a systematic review and meta-analysis","volume":"24","author":"Salmen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156494_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2022.07.017","article-title":"Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group","volume":"365","author":"Janez","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2026.156494_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221146371","volume":"27","author":"Muzurovi\u0107","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.metabol.2026.156494_bb0100","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/DMSO.S351982","article-title":"The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction","volume":"15","author":"Rizvi","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.metabol.2026.156494_bb0105","first-page":"1","article-title":"Targeting the incretin system in obesity and type 2 diabetes mellitus","author":"Ansari","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","article-title":"Incretin-based therapies for the treatment of obesity-related diseases","volume":"2","author":"Caruso","year":"2024","journal-title":"Npj Metab Health Dis"},{"key":"10.1016\/j.metabol.2026.156494_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.838410","article-title":"Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156494_bb0120","first-page":"140","article-title":"Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies","author":"Watkins","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154843","article-title":"Incretin-based therapies in 2021 - current status and perspectives for the future","volume":"122","author":"Rizzo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb0130","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1080\/14656566.2020.1795132","article-title":"Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile","volume":"21","author":"Muzurovi\u0107","year":"2020","journal-title":"Expert Opin"},{"key":"10.1016\/j.metabol.2026.156494_bb0135","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.3390\/ijms24108592","article-title":"Brown adipose tissue: a new potential target for glucagon-like peptide 1 receptor agonists in the treatment of obesity","volume":"24","author":"Hropot","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156494_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13300-022-01360-7","article-title":"Semaglutide in obesity: unmet needs in men","volume":"14","author":"Jensterle","year":"2023","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2026.156494_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2026.156494_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101139","article-title":"Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms","volume":"46","author":"Campbell","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0165","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170208","article-title":"The influence of glucose-dependent insulinotropic polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"125","author":"Thondam","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.metabol.2026.156494_bb0180","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb0185","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00125-017-4354-8","article-title":"GLP-1\/glucagon receptor co-agonism for treatment of obesity","volume":"60","author":"S\u00e1nchez-Garrido","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb0190","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2337\/dbi19-0004","article-title":"Repositioning glucagon action in the physiology and pharmacology of diabetes","volume":"69","author":"Finan","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0195","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2337\/db16-0240","article-title":"Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation","volume":"65","author":"F\u00e6rch","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0200","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00125-016-3950-3","article-title":"Glucagon action in the brain","volume":"59","author":"Abraham","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb0205","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2026.156494_bb0210","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.3390\/ijms20215407","article-title":"Glucagon regulation of energy expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156494_bb0215","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41366-022-01223-y","article-title":"The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis","volume":"46","author":"Frampton","year":"2022","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2026.156494_bb0220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2337\/db16-0746","article-title":"Effects of 13-hour hyperglucagonemia on energy expenditure and hepatic glucose production in humans","volume":"66","author":"Chakravarthy","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0225","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/oby.23141","article-title":"Prolonged glucagon infusion does not affect energy expenditure in individuals with overweight\/obesity: a randomized trial","volume":"29","author":"Whytock","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2026.156494_bb0230","first-page":"45","article-title":"Metabolic effects of glucagon in humans","volume":"15","author":"Adeva-Andany","year":"2019","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb0235","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.3390\/ijms20163905","article-title":"Glucagon control on food intake and energy balance","volume":"20","author":"Al-Massadi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156494_bb0240","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1210\/jc.2018-00050","article-title":"Hemodynamic effects of glucagon: a literature review","volume":"103","author":"Petersen","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0245","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016828","article-title":"High-dose glucagon has hemodynamic effects regardless of cardiac Beta-adrenoceptor blockade: a randomized clinical trial","volume":"9","author":"Petersen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2026.156494_bb0250","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-018-0791-z","article-title":"Does glucagon have a positive inotropic effect in the human heart?","volume":"17","author":"Hern\u00e1ndez-Cascales","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2026.156494_bb0255","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12933-016-0440-3","article-title":"Glucagon and heart in type 2 diabetes: new perspectives","volume":"15","author":"Ceriello","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2026.156494_bb0260","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphys.2019.00413","article-title":"Glucagon receptor signaling and lipid metabolism","volume":"10","author":"Galsgaard","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.metabol.2026.156494_bb0265","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0270","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/dom.14196","article-title":"A look to the future in non-alcoholic fatty liver disease: are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?","volume":"22","author":"Vincent","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0275","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.3390\/jcm9124049","article-title":"The vicious circle of hepatic glucagon resistance in non-alcoholic fatty liver disease","volume":"9","author":"Galsgaard","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0280","article-title":"The role of incretin hormones and glucagon in patients with liver disease","volume":"64","author":"Junker","year":"2017","journal-title":"Dan Med J"},{"key":"10.1016\/j.metabol.2026.156494_bb0285","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.3748\/wjg.v20.i40.14821","article-title":"Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation","volume":"20","author":"Wang","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2026.156494_bb0290","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1463-1326.2011.01454.x","article-title":"Physiologic action of glucagon on liver glucose metabolism","volume":"13","author":"Ramnanan","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.metabol.2026.156494_bb0295","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2337\/dc15-0754","article-title":"Effect of repeated glucagon doses on hepatic glycogen in type 1 diabetes: implications for a bihormonal closed-loop system","volume":"38","author":"Castle","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.735019","article-title":"Striking the balance: GLP-1\/glucagon co-agonism as a treatment strategy for obesity","volume":"12","author":"Hope","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156494_bb0305","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0315","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2337\/db13-1609","article-title":"GLP-1\/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet","volume":"63","author":"Clemmensen","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0320","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ejmech.2017.07.046","article-title":"A novel glucagon-like peptide-1\/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects","volume":"138","author":"Zhou","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.metabol.2026.156494_bb0325","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1021\/acs.jmedchem.7b00174","article-title":"Design of novel exendin-based dual glucagon-like peptide 1 (GLP-1)\/glucagon receptor agonists","volume":"60","author":"Evers","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2026.156494_bb0330","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.metabol.2026.156494_bb0335","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.metabol.2026.156494_bb0345","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101109","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","volume":"46","author":"Sonne","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0355","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2337\/db19-0849","article-title":"Amylin\/calcitonin receptor-mediated signaling in POMC neurons influences energy balance and locomotor activity in chow-fed male mice","volume":"69","author":"Coester","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0360","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1124\/mol.104.008615","article-title":"Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes","volume":"67","author":"Hay","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.metabol.2026.156494_bb0365","article-title":"Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat","volume":"11","author":"Mathiesen","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156494_bb0370","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin - its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity","volume":"8","author":"Boyle","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? - comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2026.156494_bb0380","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0385","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control","volume":"11","author":"Boyle","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0390","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.physbeh.2007.03.017","article-title":"Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin","volume":"91","author":"Osto","year":"2007","journal-title":"Physiol Behav"},{"key":"10.1016\/j.metabol.2026.156494_bb0395","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-011-2332-0","article-title":"Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C\u2082C\u2081\u2082 muscle and AML12 liver cell lines","volume":"55","author":"Moon","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: an update and future directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb0405","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1210\/en.2012-2172","article-title":"Amylin acts in the central nervous system to increase sympathetic nerve activity","volume":"154","author":"Fernandes-Santos","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2026.156494_bb0410","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1097\/00004872-200018110-00012","article-title":"Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk","volume":"18","author":"Kailasam","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2026.156494_bb0415","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/01.HYP.26.3.460","article-title":"Amylin stimulates plasma renin concentration in humans","volume":"26","author":"Cooper","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2026.156494_bb0420","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1210\/jc.2006-1980","article-title":"Amylin and hypertension: association of an amylin -G132A gene mutation and hypertension in humans and amylin-induced endothelium dysfunction in rats","volume":"92","author":"Novials","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0425","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/VHRM.S1978","article-title":"Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk","volume":"4","author":"Hoogwerf","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.metabol.2026.156494_bb0430","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/oby.2007.239","article-title":"Amylin and its relation to insulin and lipids in obese children before and after weight loss","volume":"15","author":"Reinehr","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2026.156494_bb0435","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1185\/030079908X253537","article-title":"Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes","volume":"24","author":"Wysham","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.metabol.2026.156494_bb0440","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1475-2840-9-45","article-title":"Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors","volume":"9","author":"Kurukulasuriya","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2026.156494_bb0445","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1042\/bst0230325","article-title":"Amylin regulation of carbohydrate metabolism","volume":"23","author":"Young","year":"1995","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.metabol.2026.156494_bb0450","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2026.156494_bb0455","article-title":"Cagrilintide: a Long-acting amylin analog for the treatment of obesity","author":"D\u2019Ascanio","year":"2023","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.metabol.2026.156494_bb0460","doi-asserted-by":"crossref","first-page":"E598","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog","volume":"313","author":"Gydesen","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175397","article-title":"Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin","volume":"938","author":"Melander","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2026.156494_bb0470","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12902-020-00678-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.metabol.2026.156494_bb0475","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrendo.2013.47","article-title":"Emerging combinatorial hormone therapies for the treatment of obesity and T2DM","volume":"9","author":"Sadry","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb0480","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s13300-025-01733-8","article-title":"Amylin: from mode of action to future clinical potential in diabetes and obesity","volume":"16","author":"Vol\u010dan\u0161ek","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2026.156494_bb0485","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1113\/jphysiol.2008.164269","article-title":"The role of peptide YY in appetite regulation and obesity","volume":"587","author":"Karra","year":"2009","journal-title":"J Physiol"},{"key":"10.1016\/j.metabol.2026.156494_bb0490","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/en.2005-0237","article-title":"Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively","volume":"146","author":"Neary","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2026.156494_bb0495","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/0016-5085(85)90211-2","article-title":"Human distribution and release of a putative new gut hormone, peptide YY","volume":"89","author":"Adrian","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2026.156494_bb0500","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2026.156494_bb0505","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature00887","article-title":"Gut hormone PYY(3-36) physiologically inhibits food intake","volume":"418","author":"Batterham","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2026.156494_bb0510","doi-asserted-by":"crossref","first-page":"E1062","DOI":"10.1152\/ajpendo.00450.2006","article-title":"Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects","volume":"292","author":"Sloth","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0515","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2006-1806","article-title":"Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults","volume":"92","author":"Gantz","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0520","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2337\/cd19-0079","article-title":"Oral semaglutide","volume":"38","author":"Hughes","year":"2020","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0525","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s13300-022-01226-y","article-title":"Effect of oral semaglutide on cardiovascular parameters and their mechanisms in patients with type 2 diabetes: rationale and design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)","volume":"13","author":"Jani\u0107","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2026.156494_bb0530","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231211402","article-title":"Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience","volume":"51","author":"Jani\u0107","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.metabol.2026.156494_bb0535","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb0540","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.metabol.2026.156494_bb0545","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.metabol.2026.156494_bb0550","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2213-8587(25)00225-6","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial","volume":"13","author":"Lingvay","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb0555","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0560","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0565","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.metabol.2026.156494_bb0570","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0575","author":"Pfizer Inc"},{"key":"10.1016\/j.metabol.2026.156494_bb0580","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.16005","article-title":"Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: a dose-ranging, phase 2, randomized, placebo-controlled study","volume":"27","author":"Amin","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0585","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/dom.15150","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0590","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/dom.15184","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0595","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0600","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb0605","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0610","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/dom.14794","article-title":"In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist","volume":"24","author":"Jones","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0615","doi-asserted-by":"crossref","DOI":"10.2337\/db23-765-P","article-title":"765-P: a single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in obese individuals without diabetes","volume":"72","author":"Thennati","year":"2023","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2026.156494_bb0620","first-page":"S320","article-title":"SO-636 a single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes","volume":"66","author":"Thennati","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb0625","doi-asserted-by":"crossref","DOI":"10.2337\/db23-766-P","article-title":"766-P: safety and tolerability of once-weekly GL0034 (utreglutide) in healthy individuals\u2014a multiple ascending dose study","volume":"72","author":"Thennati","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101762","article-title":"Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog","volume":"75","author":"Guo","year":"2023","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0635","article-title":"79-LB: an open-label, active-controlled phase 2 evaluation of novel GLP-1 analog ecnoglutide in adults with obesity","volume":"72","author":"Zhu","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(25)00141-X","article-title":"Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","author":"Ji","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106218","article-title":"Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys","volume":"175","author":"Liao","year":"2022","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.metabol.2026.156494_bb0650","article-title":"757-P: efficacy and safety of supaglutide monotherapy in patients with type 2 diabetes","volume":"72","author":"Wang","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0655","doi-asserted-by":"crossref","DOI":"10.2337\/db23-778-P","article-title":"778-P: efficacy and safety of supaglutide as add-on to metformin in patients with type 2 diabetes","volume":"72","author":"Anwar","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0660","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bcp.2018.01.029","article-title":"Glutazumab, a novel long-lasting GLP-1\/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites","volume":"150","author":"Li","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.metabol.2026.156494_bb0665","author":"GMAX"},{"key":"10.1016\/j.metabol.2026.156494_bb0670","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00125-021-05392-9","article-title":"Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study","volume":"64","author":"Ji","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb0675","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13318-020-00665-x","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple escalating doses of PEGylated exenatide (PB-119) in healthy volunteers","volume":"46","author":"Cui","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.metabol.2026.156494_bb0680","article-title":"PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-na\u00efve type 2 diabetes mellitus patients","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2026.156494_bb0685","doi-asserted-by":"crossref","DOI":"10.2337\/db23-770-P","article-title":"770-P: efficacy and safety of once-weekly PB-119 monotherapy vs. placebo in Chinese patients with type 2 diabetes in a randomized controlled trial","volume":"72","author":"Pegbio Study Group","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0690","doi-asserted-by":"crossref","DOI":"10.2337\/db23-760-P","article-title":"760-P: discovery of GSBR-1290, a highly potent, orally available, novel Small molecule GLP-1 receptor agonist","volume":"72","author":"Mao","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0695","doi-asserted-by":"crossref","DOI":"10.2337\/db23-754-P","article-title":"754-P: a first-in-human single ascending dose study of GSBR-1290, a novel small molecule GLP-1 receptor agonist, in healthy volunteers","volume":"72","author":"Coll","year":"2023","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.metabol.2026.156494_bb0700","doi-asserted-by":"crossref","DOI":"10.2337\/db24-767-P","article-title":"767-P: a phase 1b\/2a study of the safety and tolerability of GSBR-1290, a novel oral small molecule glucagon-like peptide 1 receptor agonist (GLP-1RA), in healthy overweight\/obese volunteers (HOV) and participants with type 2 diabetes mellitus (T2DM)","volume":"73","author":"Coll","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0705","doi-asserted-by":"crossref","DOI":"10.2337\/db23-767-P","article-title":"767-P: TERN-601, a novel oral GLP-1R agonist, suppresses food intake and improves glucose tolerance in transgenic mice expressing human GLP-1 receptor","volume":"72","author":"Jones","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0710","author":"Genentech"},{"key":"10.1016\/j.metabol.2026.156494_bb0715","doi-asserted-by":"crossref","DOI":"10.2337\/db23-56-OR","article-title":"56-OR: a Long-acting glucose-dependent insulinotropic polypeptide receptor agonist shows weight loss without nausea or vomiting","volume":"72","author":"Knop","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0720","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2026.156494_bb0725","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb0730","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0740","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0745","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2026.156494_bb0755","first-page":"S31","article-title":"CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in 4 weeks in overweight and obese adults","volume":"66","author":"Chakravarthy","year":"2023","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2026.156494_bb0760","article-title":"Glycemic control, weight reduction, and safety with CT 388: a signal biased dual GLP 1\/GIP receptor agonist\u2014results from a 12-week cohort in adults with obesity and type\u00a02 diabetes","volume":"74","author":"Steinberg","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0765","doi-asserted-by":"crossref","DOI":"10.1111\/DOM.70006\/v2\/response1","article-title":"Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: a double-blind, randomized placebo-controlled phase 2 trial","author":"Chakravarthy","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0770","doi-asserted-by":"crossref","DOI":"10.2337\/db23-774-P","article-title":"774-P: weight-independent effects of CT-868, a signaling biased dual GLP-1\/GIP receptor modulator, on glucose homeostasis in overweight and obese adults with type 2 diabetes","volume":"72","author":"Chakravarthy","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0775","doi-asserted-by":"crossref","DOI":"10.2337\/db23-763-P","article-title":"763-P: safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1\/GIP receptor agonist (HRS9531) in healthy subjects\u2014a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose (SAD and MAD) study","volume":"72","author":"He","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0780","author":"Scohia Pharma, Inc"},{"key":"10.1016\/j.metabol.2026.156494_bb0785","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0790","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0795","author":"Hanmi Pharmaceutical Co., Ltd"},{"key":"10.1016\/j.metabol.2026.156494_bb0800","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/dom.14412","article-title":"Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes","volume":"23","author":"Asano","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0805","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0810","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz047","article-title":"Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist","volume":"105","author":"Parker","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0815","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb0820","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101801","article-title":"Results from three phase 1 trials of NNC9204-1177, a glucagon\/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity","volume":"78","author":"Friedrichsen","year":"2023","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0830","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb0835","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.metabol.2026.156494_bb0840","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0845","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/dom.14394","article-title":"Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1\/glucagon receptor agonist SAR425899 in comparison with liraglutide","volume":"23","author":"Schiavon","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0850","author":"OPKO"},{"key":"10.1016\/j.metabol.2026.156494_bb0855","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156494_bb0860","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2026.156494_bb0865","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2337\/db24-262-OR","article-title":"Pemvidutide, a GLP 1\/glucagon dual\u00a0receptor\u00a0agonist, in subjects with overweight or obesity \u2013 a 48 week, placebo controlled, phase 2 (MOMENTUM) trial","volume":"73","author":"Aronne","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0870","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156494_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.metabol.2026.156494_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101088","article-title":"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study","volume":"39","author":"Ji","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.metabol.2026.156494_bb0885","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1038\/s41467-022-31328-x","article-title":"A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2026.156494_bb0890","article-title":"Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial","author":"Zhang","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb0895","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0900","volume":"72","author":"To D","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb0905","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb0910","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(21)00944-2","article-title":"Cagrilintide plus semaglutide for obesity management","volume":"397","author":"Becerril","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb0915","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.metabol.2026.156494_bb0920","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.metabol.2026.156494_bb0925","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0930","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb0935","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0940","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist Retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0945","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb0950","first-page":"1","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156494_bb0955","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cmet.2021.12.010","article-title":"GLP-1\/GIP\/glucagon receptor triagonism gets its try in humans","volume":"34","author":"Finan","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0960","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107176","article-title":"A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - study design and rationale of HM-TRIA-201 study","volume":"130","author":"Abdelmalek","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.metabol.2026.156494_bb0975","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/dom.14358","article-title":"Safety and efficacy of an extended-release peptide YY analogue for obesity: a randomized, placebo-controlled, phase 1 trial","volume":"23","author":"Tan","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0980","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","article-title":"GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss\u2014chemistry, physiology, and clinical applications","volume":"35","author":"Campbell","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb0985","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab065","article-title":"The role of incretins on insulin function and glucose homeostasis","volume":"162","author":"Holst","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2026.156494_bb0990","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: the role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170213","article-title":"The role of GIP in \u03b1-cells and glucagon secretion","volume":"125","author":"El","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.metabol.2026.156494_bb1000","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(23)01291-6","article-title":"CagriSema and the link between obesity and type 2 diabetes","volume":"402","author":"Apovian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb1005","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170183","article-title":"Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists","volume":"125","author":"Gasbjerg","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.metabol.2026.156494_bb1015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00125-008-0943-x","article-title":"Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes","volume":"51","author":"H\u00f8jberg","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb1020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/DDDT.S358989","article-title":"Designing a dual GLP-1R\/GIPR agonist from tirzepatide: comparing residues between tirzepatide, GLP-1, and GIP","volume":"16","author":"Wang","year":"2022","journal-title":"DDDT"},{"key":"10.1016\/j.metabol.2026.156494_bb1025","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnz002","article-title":"Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists = antagonists?","volume":"41","author":"Killion","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2026.156494_bb1030","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.celrep.2018.01.065","article-title":"Glucagon receptor antagonism improves glucose metabolism and cardiac function by promoting AMP-mediated protein kinase in diabetic mice","volume":"22","author":"Sharma","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.metabol.2026.156494_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170296","article-title":"Glucagon-based therapy: past, present and future","volume":"127","author":"Patil","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.metabol.2026.156494_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110872","article-title":"Glucagon-receptor-antagonism-mediated \u03b2-cell regeneration as an effective anti-diabetic therapy","volume":"39","author":"Xi","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.metabol.2026.156494_bb1045","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/er.2018-00117","article-title":"Targeting the incretin\/glucagon system with triagonists to treat diabetes","volume":"39","author":"Capozzi","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2026.156494_bb1050","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156494_bb1055","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2337\/dc06-1549","article-title":"Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes","volume":"30","author":"Laferr\u00e8re","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb1060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1262-3636(09)73458-5","article-title":"Effect of gastric bypass surgery on the incretins","volume":"35","author":"Laferr\u00e8re","year":"2009","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb1065","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1038\/ijosup.2016.8","article-title":"Bariatric surgery and obesity: influence on the incretins","volume":"6","author":"Laferr\u00e8re","year":"2016","journal-title":"Int J Obes Suppl"},{"key":"10.1016\/j.metabol.2026.156494_bb1070","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/SLA.0b013e3181a6cdb0","article-title":"Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels","volume":"249","author":"Oliv\u00e1n","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.metabol.2026.156494_bb1075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1753-0407.2009.00064.x","article-title":"Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery","volume":"2","author":"Bose","year":"2010","journal-title":"J Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb1080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fendo.2018.00530","article-title":"Weight-independent mechanisms of glucose control after Roux-en-Y gastric bypass","volume":"9","author":"Laferr\u00e8re","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156494_bb1085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12020-011-9514-x","article-title":"Do we really know why diabetes remits after gastric bypass surgery?","volume":"40","author":"Laferr\u00e8re","year":"2011","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.metabol.2026.156494_bb1090","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1210\/endo-94-4-1139","article-title":"Effects of the gastric inhibitory polypeptide present in impure pancreozymin-cholecystokinin on plasma insulin and glucagon in the rat","volume":"94","author":"Rabinovitch","year":"1974","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2026.156494_bb1095","first-page":"487","article-title":"Identification and actions of gastric inhibitory polypeptide","volume":"31","author":"Brown","year":"1975","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.metabol.2026.156494_bb1100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dbi20-0049","article-title":"Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials","volume":"71","author":"Ussher","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb1105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.metabol.2026.156494_bb1110","first-page":"151","article-title":"Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond","author":"Tsilingiris","year":"2024","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb1115","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb1120","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.metabol.2026.156494_bb1125","first-page":"1","article-title":"Signaling pathways in obesity: mechanisms and therapeutic interventions","volume":"7","author":"Wen","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.metabol.2026.156494_bb1130","first-page":"142","article-title":"Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy","author":"Chakhtoura","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb1135","first-page":"145","article-title":"The key role of inflammation in the pathogenesis and management of obesity and CVD","author":"Boutari","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb1140","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.metabol.2026.156494_bb1145","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156494_bb1150","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb1155","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1366940","article-title":"The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study","volume":"15","author":"Jensterle","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156494_bb1160","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1210\/clinem\/dgab848","article-title":"New Horizons. A new paradigm for treating to target with second-generation obesity medications","volume":"107","author":"Garvey","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2026.156494_bb1165","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00125-023-06057-5","article-title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study","volume":"67","author":"Krishnan","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb1170","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.numecd.2022.07.001","article-title":"Effect of pharmacological interventions and placebo on liver histology in nonalcoholic steatohepatitis: a network meta-analysis","volume":"32","author":"Pennisi","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2026.156494_bb1175","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1180","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1185","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.metabol.2026.156494_bb1190","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Supplement 1","key":"10.1016\/j.metabol.2026.156494_bb1195","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S0168-8278(24)00560-9","article-title":"OS-119 Survodutide (BI 456906), a glucagon receptor\/glucagon-like peptide-1 receptor (GCGR\/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial","volume":"80","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"issue":"Supplement 1","key":"10.1016\/j.metabol.2026.156494_bb1200","doi-asserted-by":"crossref","first-page":"S610","DOI":"10.1016\/S0168-8278(24)01779-3","article-title":"Real-world use of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated Steatotic liver disease (MASLD): a cross-sectional analysis from TARGET-NASH (SAT-212)","volume":"80","author":"Barritt","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156494_bb1205","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1210","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb1215","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156494_bb1220","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.molmet.2017.08.010","article-title":"The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice","volume":"6","author":"Baggio","year":"2017","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb1225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2026.156494_bb1230","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2337\/dc20-1318","article-title":"Glucose-dependent Insulinotropic peptide in the high-normal range is associated with increased carotid intima-media thickness","volume":"44","author":"Juji\u0107","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb1235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.metabol.2026.156494_bb1240","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"0","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1245","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1250","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy","volume":"66","author":"Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb1255","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2021.12.018","article-title":"Renal outcomes associated with glucose-lowering agents: systematic review and meta-analysis of randomized outcome trials","volume":"97","author":"Chalmoukou","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1260","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.metabol.2026.156494_bb1265","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1270","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb1275","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156494_bb1280","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1285","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.metabol.2026.156494_bb1290","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2026.156494_bb1295","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study","volume":"15","author":"Scott Butsch","year":"2025","journal-title":"Obes Pillars"},{"key":"10.1016\/j.metabol.2026.156494_bb1300","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.metabol.2026.156494_bb1305","article-title":"Sarcopenia: still in relative definition-penia and severe treatment-penia","volume":"150","author":"Polyzos","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb1310","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155676","article-title":"Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease","volume":"147","author":"Polyzos","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb1315","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155577","article-title":"Interplay of skeletal muscle and adipose tissue: sarcopenic obesity","volume":"144","author":"Park","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb1320","article-title":"Epidemiology of sarcopenia: prevalence, risk factors, and consequences","volume":"144","author":"Yuan","year":"2023","journal-title":"Metabolism"},{"issue":"Suppl. 4","key":"10.1016\/j.metabol.2026.156494_bb1325","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb1330","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2026.156494_bb1335","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155711","article-title":"Pathophysiology of sarcopenia: genetic factors and their interplay with environmental factors","volume":"149","author":"Aslam","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb1340","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155639","article-title":"Sarcopenic obesity: emerging mechanisms and therapeutic potential","volume":"146","author":"Axelrod","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb1345","first-page":"146","article-title":"Diet for the prevention and management of sarcopenia","author":"Calvani","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb1350","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1355","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.3390\/jcm13206269","article-title":"The effect of glucagon-like-peptide-1 receptor agonists on diabetic retinopathy progression, central subfield thickness, and response to intravitreal injections","volume":"13","author":"Michaeli","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1360","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.metabol.2026.156494_bb1365","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100547","article-title":"The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center","volume":"4","author":"Joo","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.metabol.2026.156494_bb1370","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0140-6736(82)90464-0","article-title":"Worsening of diabetic retinopathy with strict control of blood sugar","volume":"2","author":"Hooymans","year":"1982","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.metabol.2026.156494_bb1375","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109148","article-title":"Semaglutide and the retina: weighing evidence against concern","volume":"39","author":"Muzurovi\u0107","year":"2025","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.metabol.2026.156494_bb1380","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2026.156494_bb1385","first-page":"611","article-title":"Weight loss drugs linked with lower risk of 10 cancers","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156494_bb1390","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.metabol.2026.156494_bb1395","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12876-025-04211-4","article-title":"Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies","volume":"25","author":"Zhong","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.metabol.2026.156494_bb1400","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bph.15446","article-title":"Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: alternative approaches for treatment of Type 2 diabetes","volume":"179","author":"Malik","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2026.156494_bb1405","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3803\/EnM.2021.102","article-title":"Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists","volume":"36","author":"Choe","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.metabol.2026.156494_bb1410","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1170181","article-title":"Variation in responses to incretin therapy: modifiable and non-modifiable factors","volume":"10","author":"Austin","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.metabol.2026.156494_bb1415","first-page":"149","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","author":"Karakasis","year":"2023","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb1420","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.apsb.2022.11.008","article-title":"Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition","volume":"13","author":"Xie","year":"2023","journal-title":"Acta Pharma Sin B"},{"key":"10.1016\/j.metabol.2026.156494_bb1425","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0898-6568(01)00258-3","article-title":"G protein-coupled receptor signalling and cross-talk: achieving rapidity and specificity","volume":"14","author":"Hur","year":"2002","journal-title":"Cell Signal"},{"key":"10.1016\/j.metabol.2026.156494_bb1430","first-page":"116","article-title":"Effects of naturally occurring genetic variations in incretin receptors on glucose homeostasis","author":"Gaur","year":"2021","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb1435","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1\u2013induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156494_bb1440","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13731","article-title":"Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance","volume":"75","author":"Jain","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.metabol.2026.156494_bb1445","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cmet.2017.04.013","article-title":"A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism","volume":"25","author":"Grasset","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156494_bb1450","author":"Ally"},{"key":"10.1016\/j.metabol.2026.156494_bb1455","author":"Institute for Clinical and Economic Review (ICER)"},{"key":"10.1016\/j.metabol.2026.156494_bb1460","author":"Froistad"},{"key":"10.1016\/j.metabol.2026.156494_bb1465","doi-asserted-by":"crossref","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial","author":"Lam","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"1 Suppl 1","key":"10.1016\/j.metabol.2026.156494_bb1470","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb1475","article-title":"Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities","volume":"11","author":"Sarzani","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.metabol.2026.156494_bb1480","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41366-024-01525-3","article-title":"The past, present, and future of behavioral obesity treatment","volume":"49","author":"Chao","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2026.156494_bb1485","first-page":"1","article-title":"Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn","author":"Murphy","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2026.156494_bb1490","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jhn.12853","article-title":"Group versus one-to-one multi-component lifestyle interventions for weight management: a systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Abbott","year":"2021","journal-title":"J Hum Nutr Diet"},{"issue":"1 Suppl 1","key":"10.1016\/j.metabol.2026.156494_bb1495","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc25-S005","article-title":"5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb1500","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156494_bb1505","doi-asserted-by":"crossref","DOI":"10.2174\/0113816128378484250619080753","article-title":"Incretin-based agents and metabolic dysfunction-associated steatotic liver disease","author":"Muzurovi\u0107","year":"2025","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.metabol.2026.156494_bb1510","article-title":"DCRM 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"0","author":"Handelsman","year":"2024","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb1515","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.scispo.2022.11.008","article-title":"Patterns of health enhancing physical activity in older patients with diabetes mellitus","volume":"39","author":"Vol\u010dan\u0161ek","year":"2024","journal-title":"Sci Sports"},{"key":"10.1016\/j.metabol.2026.156494_bb1520","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154873","article-title":"Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk","volume":"124","author":"van den Hoek","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb1525","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","article-title":"Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study","volume":"2","author":"Li","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb1530","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13668-014-0099-x","article-title":"The Look AHEAD Trial: a review and discussion of its outcomes","volume":"3","author":"Pi-Sunyer","year":"2014","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.metabol.2026.156494_bb1535","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13679-023-00534-z","article-title":"The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical opportunities","volume":"12","author":"Wadden","year":"2023","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.metabol.2026.156494_bb1540","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Look AHEAD Research Group","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb1545","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa061883","article-title":"A self-regulation program for maintenance of weight loss","volume":"355","author":"Wing","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1550","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1007\/s00125-020-05249-7","article-title":"Effects of an intensive lifestyle intervention on the underlying mechanisms of improved glycaemic control in individuals with type 2 diabetes: a secondary analysis of a randomised clinical trial","volume":"63","author":"Johansen","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156494_bb1555","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7326\/0003-4819-143-9-200511010-00010","article-title":"Meta-analysis: secondary prevention programs for patients with coronary artery disease","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1560","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb1565","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look AHEAD Research Group","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1570","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069719","article-title":"Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomised controlled trials","volume":"377","author":"Madigan","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2026.156494_bb1575","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2337\/dc21-2216","article-title":"ADA\/EASD precision medicine in diabetes initiative: an international perspective and future vision for precision medicine in diabetes","volume":"45","author":"Nolan","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb1580","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2024.100283","article-title":"Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study","volume":"22","author":"Zakaria","year":"2024","journal-title":"Metabol Open"},{"key":"10.1016\/j.metabol.2026.156494_bb1585","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2337\/dc15-1942","article-title":"Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders","volume":"39","author":"Steven","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb1590","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156494_bb1595","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156494_bb1600","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2026.156494_bb1605","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1610","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.metabol.2026.156494_bb1615","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156494_bb1620","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13717","article-title":"Potent incretin-based therapy for obesity: a systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety","volume":"25","author":"M\u00fcllertz","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.metabol.2026.156494_bb1625","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156494_bb1630","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.metabol.2026.156494_bb1635","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13679-025-00623-1","article-title":"Dual and triple gut peptide agonists on the horizon for the treatment of type 2 diabetes and obesity. An overview of preclinical and clinical data","volume":"14","author":"Anastasiou","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.metabol.2026.156494_bb1640","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2026.156494_bb1645","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13483","article-title":"The effectiveness of technology-based interventions for weight loss maintenance: a systematic review of randomized controlled trials with meta-analysis","volume":"23","author":"Mamalaki","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.metabol.2026.156494_bb1650","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.0821","article-title":"An adaptive behavioral intervention for weight loss management: a randomized clinical trial","author":"Spring","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156494_bb1655","article-title":"Lifestyle interventions for obesity in the era of GLP-1 receptor agonists","author":"Ard","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156494_bb1660","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/oby.23962","article-title":"Game changers: do new medications make lifestyle-based treatment of obesity obsolete?","volume":"32","author":"Lewis","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2026.156494_bb1665","first-page":"1","article-title":"What is the evidence regarding the safety of new obesity pharmacotherapies","author":"Vidal","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2026.156494_bb1670","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000521264","article-title":"Glucagon-like peptide-1 receptor agonists in the treatment of obesity","volume":"96","author":"Jensterle","year":"2023","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.metabol.2026.156494_bb1675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(24)00003-5","article-title":"Treating obesity and diabetes: drugs alone are not enough","volume":"403","author":"Lancet","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156494_bb1680","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155401","article-title":"Adherence to the EAT-Lancet diet, genetic susceptibility, and risk of type 2 diabetes in Swedish adults","volume":"141","author":"Zhang","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156494_bb1685","first-page":"123","article-title":"Dietary carbohydrate intake and new-onset diabetes: a nationwide cohort study in China","author":"Zhou","year":"2021","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2026.156494_bb1690","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/17512433.2022.2108400","article-title":"Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes","volume":"15","author":"Rizzo","year":"2022","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952600003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952600003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:37:56Z","timestamp":1770889076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604952600003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":336,"alternative-id":["S002604952600003X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156494","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging incretin- and multi-agonist-based treatments \u2013 the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156494"}}